Acute myeloid leukemia trials in Austria

In Austria 14 Also abroad 761

14 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Where
Feldkirch, Linz, Vienna
Age
18 years and over
People
875 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07223814 · EU 2025-522767-15-00
Phase 3Taking people
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
Where
Innsbruck, Linz, Rankweil, Salzburg, Vienna
Age
18 years to 75 years
People
650 worldwide
Run by
University of Ulm
See details and how to joinNCT04628026 · EU 2023-507518-28-00
Phase 3Taking people
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Where
Linz, Salzburg, Vienna, Wels
Age
18 years and over
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06852222 · EU 2024-520154-38-00
Phase 2/3Taking people
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Where
Graz, Linz, St. Poelten, Vienna
Age
18 years and over
People
660 worldwide
Run by
AbbVie
See details and how to joinNCT07581002 · EU 2025-523724-47-00
Phase 3Taking people
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
Where
Feldkirch, Innsbruck, Salzburg, Vienna
Age
18 years and over
People
180 worldwide
Run by
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
See details and how to join2024-512753-24-00 · EU 2024-512753-24-00
Phase 3Taking people
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Where
Graz, Innsbruck, Klagenfurt Am Woerthersee, Leoben, Linz, St. Poelten, Vienna
Age
12 years and over
People
468 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00
Phase 1Taking people
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
Where
Vienna
Age
0 years to 21 years
People
20 worldwide
Run by
PedAL BCU, LLC
See details and how to joinNCT06376162 · EU 2023-505262-28-00
Phase 2Taking people
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Where
Vienna
Age
18 years and over
People
140 worldwide
Run by
Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00
Phase 3Taking people
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Where
Feldkirch, Linz, Salzburg, Vienna
Age
18 years and over
People
448 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT06652438 · EU 2024-512733-32-00
Phase 2Taking people
Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)
Where
Vienna
Age
Up to 64 years
People
31 worldwide
Run by
Pediatric Research International GmbH
See details and how to join2025-521390-14-00 · EU 2025-521390-14-00
Phase 2Enrolling by invitation
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Where
Vienna
Age
18 years and over
People
332 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04093570 · EU 2024-516293-29-01
Phase 3Taking people
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
Where
Linz, Vienna, Wels
Age
18 years and over
People
245 worldwide
Run by
Servier Affaires Médicales
See details and how to joinNCT05907057 · EU 2022-501709-11-00
No phaseTaking people
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project
Where
Graz, Innsbruck, Linz, Rankweil, Salzburg, Vienna
Age
18 years and over
People
50,000 worldwide
Run by
University of Ulm
See details and how to joinNCT01252485
Phase 3Taking people
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Where
Feldkirch, Salzburg, Vienna
Age
18 years and over
People
227 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07075016